Latest Media Releases (Page 7) | Finance News Network

Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Immutep Quarterly Activities Report and Appendix 4C (ASX:IMM)

-- Excellent clinical data reported from TACTI-002 Phase II trial, including median Overall Survival of 35.5 months in first line non-small cell lung cancer (1L NSCLC) patients expressing PD-L1 (TPS...read more

Next Science - Appendix 4C & Quarterly Activity Report - 31 December 2023 (ASX:NXS)

-- FY23 Revenue of US$22.2m, up 89.4% on pcp2 with 2H FY23 revenue of US$12.1m in line with 2H FY23 guidance of US$12m-14m provided in October 2023. -- 4Q FY23 Product Sales of US$7.1m, up 123.5% o...read more

Radiopharm Theranostics - Investor Presentation (ASX:RAD)

To view the presentation, download the attached PDF.

Radiopharm Theranostics - Placement of Entitlement Offer Shortfall (ASX:RAD)

On 31 October 2023, Radiopharm Theranostics Limited (ASX:RAD) (Radiopharm or Company) announced the details of a non-renounceable entitlement offer (Entitlement Offer) to raise approximate...read more

Chimeric Therapeutics - Placement of Entitlement Offer Shortfall (ASX:CHM)

-- Placement of Entitlement Offer Shortfall of approx. $3.20m from institutional and sophisticated investors -- Takes the total amount subscribed under the entitlement offer and entitlement offer s...read more

Chimeric Therapeutics - ADVENT-AML Phase 1B clinical trial open to enrolment (ASX:CHM)

-- ADVENT-AML (CHM 0201 + Azacitidine + Venetoclax) Phase 1B clinical trial now open to enrollment at The University of Texas MD Anderson Cancer Center -- Enrolment open to patients with relapsed /...read more

Chimeric Therapeutics receives $7.36M R&D tax incentive (ASX:CHM)

Sydney, Australia, 10 January 2024: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell, is pleased announce it has received a research...read more

Immutep Corporate Presentation (ASX:IMM)

To view the presentation, download the attached PDF.

Immutep - First Patient Dosed in Urothelial Cancer INSIGHT-005 Trial (ASX:IMM)

SYDNEY, AUSTRALIA – 04 January 2024 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing nove...read more

Austco Healthcare's Teknocorp Secures $1.2m Contract (ASX:AHC)

Austco Healthcare Limited (ASX: AHC) is pleased to announce that Teknocorp, its recently acquired subsidiary, has been awarded an AUD $1.2 million contract to deliver state-of-the-art access control...read more

Radiopharm Theranostics - 2nd Australian site for Nanomab-PDL-1 Phase 1 trial (ASX:RAD)

-- Ethics Committee approval received from Hollywood Private Hospital in Perth, WA -- Patient recruitment to commence shortly -- Phase 1 study in 21 patients designed to evaluate the safety and ef...read more

Immutep - Change of Registered Office Address (ASX:IMM)

SYDNEY, AUSTRALIA – 22 December 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), advises that its registered office and principal plac...read more

Radiopharm Theranostics - Phase 1 Therapeutic NSCLC (Lung Cancer) Trial Opens 4 Jan (ASX:RAD)

-- Successful Site Initiation at Princess Alexandra Hospital, Brisbane for RAD 204 (PDL-1 nanobody) therapeutic Phase 1 trial -- Phase 1 First-In-Human study in 21 patients designed to evaluate saf...read more

Next Science - XPERIENCE study findings published (ASX:NXS)

Publication of knee study showing potential anti-inflammatory benefit for XPERIENCE Next Science Limited (ASX:NXS) (“Next Science” or “the Company”) today announces the pu...read more

Immutep - PEI provides constructive feedback for ph3 lung cancer trial (ASX:IMM)

SYDNEY, AUSTRALIA – December 21, 2023 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developi...read more

Viewing: 91 - 105 of 200 Previous | Next